Literature DB >> 27356208

In silico designing of hyper-glycosylated analogs for the human coagulation factor IX.

Fahimeh Ghasemi1, Alireza Zomorodipour2, Ali Asghar Karkhane3, M Reza Khorramizadeh4.   

Abstract

N-glycosylation is a process during which a glycan moiety attaches to the asparagine residue in the N-glycosylation consensus sequence (Asn-Xxx-Ser/Thr), where Xxx can be any amino acid except proline. Introduction of a new N-glycosylation site into a protein backbone leads to its hyper-glycosylation, and may improve the protein properties such as solubility, folding, stability, and secretion. Glyco-engineering is an approach to facilitate the hyper-glycosylation of recombinant proteins by application of the site-directed mutagenesis methods. In this regard, selection of a suitable location on the surface of a protein for introduction of a new N-glycosylation site is a main concern. In this work, a computational approach was conducted to select suitable location(s) for introducing new N-glycosylation sites into the human coagulation factor IX (hFIX). With this aim, the first 45 residues of mature hFIX were explored to find out suitable positions for introducing either Asn or Ser/Thr residues, to create new N-glycosylation site(s). Our exploration lead to detection of five potential positions, for hyper-glycosylation. For each suggested position, an analog was defined and subjected for N-glycosylation efficiency prediction. After generation of three-dimensional structures, by homology-based modeling, the five designed analogs were examined by molecular dynamic (MD) simulations, to predict their stability levels and probable structural distortions caused by amino acid substitutions, relative to the native counterpart. Three out of five suggested analogs, namely; E15T, K22N, and R37N, reached equilibration state with relatively constant Root Mean Square Deviation values. Additional analysis on the data obtained during MD simulations, lead us to conclude that, R37N is the only qualified analog with the most similar structure and dynamic behavior to that of the native counterpart, to be considered for further experimental investigations.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Glyco-engineering; Human coagulation factor IX Gla domain; Hyper-glycosylation; In silico design; Molecular dynamic simulations.

Mesh:

Substances:

Year:  2016        PMID: 27356208     DOI: 10.1016/j.jmgm.2016.05.011

Source DB:  PubMed          Journal:  J Mol Graph Model        ISSN: 1093-3263            Impact factor:   2.518


  4 in total

1.  In silico docking and molecular dynamics simulation of 3-dehydroquinate synthase (DHQS) from Mycobacterium tuberculosis.

Authors:  Mustafa Alhaji Isa; Rita Singh Majumdhar; Shazia Haider
Journal:  J Mol Model       Date:  2018-05-11       Impact factor: 1.810

2.  Computational investigation of drug bank compounds against 3C-like protease (3CLpro) of SARS-CoV-2 using deep learning and molecular dynamics simulation.

Authors:  Tushar Joshi; Priyanka Sharma; Shalini Mathpal; Tanuja Joshi; Priyanka Maiti; Mahesha Nand; Veena Pande; Subhash Chandra
Journal:  Mol Divers       Date:  2021-10-12       Impact factor: 3.364

3.  Exploring the inhibitory potentials of Momordica charantia bioactive compounds against Keap1-Kelch protein using computational approaches.

Authors:  Temitope Isaac Adelusi; Misbaudeen Abdul-Hammed; Mukhtar Oluwaseun Idris; Oyedele Qudus Kehinde; Ibrahim Damilare Boyenle; Ukachi Chiamaka Divine; Ibrahim Olaide Adedotun; Ajayi Ayodeji Folorunsho; Oladipo Elijah Kolawole
Journal:  In Silico Pharmacol       Date:  2021-06-25

4.  Using Chou's 5-steps rule to study pharmacophore-based virtual screening of SARS-CoV-2 Mpro inhibitors.

Authors:  Hemlata Pundir; Tanuja Joshi; Tushar Joshi; Priyanka Sharma; Shalini Mathpal; Subhash Chandra; Sushma Tamta
Journal:  Mol Divers       Date:  2020-10-20       Impact factor: 3.364

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.